<DOC>
	<DOCNO>NCT00847860</DOCNO>
	<brief_summary>The purpose study evaluate efficacy PDE-3 inhibitor , cilostazol , prevention treatment vascular dementia , brain white matter lesion vascular risk factor .</brief_summary>
	<brief_title>Cilostazol Verse Asprin Vascular Dementia Poststroke Patients With White Matter Lesions</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Age range 40 80 year 2 . After newly ischemic stroke 3 month 2 year 3 . Brain CT MRI show stroke lesion white matter lesion , ARWMC ( Age Related White Matter Change ) &gt; =4 4 . Moderate mild cognitive deficit : MMSE 1226 5 . Vascular mixed dementia : Hachinski ischemic score &gt; 4 6 . Moderate mild disability : MRS &lt; =4 , NIHSS &lt; 20 7 . Informed consent 1 . Definitive diagnosis dementia prior stroke 2 . Cerebral hemorrhage past 3 . Cerebral embolism result cardiogenic embolus 4 . Critically ills : MRS &gt; 4 , NIHSS &gt; =20 5 . Bedridden patient hardly discover newly stroke 6. patient sever cardiac , hepatic nephric complication 7. dementia cause vascular lesion 8. disease disturb cognitive evaluation 9. susceptibility variety allergen 10. abstain Cilostazol Asprin 11. antiplatelet treatment , anticoagulation fibrinolysis need disease 12. reject participate patient family</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>cognition</keyword>
</DOC>